Menu

Generics/News

136 AA011035

Actavis hit with lawsuit over generic version of weight-loss drug

Generics/News | Posted 31/07/2015

US-based obesity specialist Orexigen Therapeutics (Orexigen) and its North American partner, Takeda Pharmaceuticals (Takeda), have sued Actavis (Allergan’s US generics business) over its generic version of the weight-loss drug Contrave (naltrexone/bupropion).

Inhaler MD002004 V13J25

Mylan launches generic asthma inhaler in UK

Generics/News | Posted 03/07/2015

US generics manufacturer Mylan announced on 8 June 2015 that it had launched the first bioequivalent alternative to GlaxoSmithKline (GSK)’s asthma inhaler Seretide/Advair (fluticasone/salmeterol) in the UK.

Generic V13C05

Generics of ADHD drug launched in US

Generics/News | Posted 26/06/2015

Shire Pharmaceutical’s (Shire’s) blockbuster attention deficit hyperactivity disorder (ADHD) drug Intuniv is now facing competition as four generics of the therapy have been launched on the US market.

picture 80

Osteoporosis and ADHD generics launched in USA

Generics/News | Posted 12/06/2015

On 1 and 2 June 2015, Israeli generics giant Teva Pharmaceutical Industries (Teva), launched its latest osteoporosis and ADHD generics, respectively.

Tivicay DD V15F04

FDA receives application for first generic of HIV drug dolutegravir

Generics/News | Posted 05/06/2015

India-based Aurobindo Pharma (Aurobindo) has submitted an abbreviated new drug application (ANDA) for HIV treatment dolutegravir for tentative approval, to the US Food and Drug Administration (FDA).

Generic V13C05

Generics of high blood pressure medication launched

Generics/News | Posted 22/05/2015

On 31 March 2015, generics majors Mylan, Sandoz and Teva Pharmaceutical Industries (Teva) announced the US launch of their respective generic amlodipine and valsartan combination tablets in four dosages.

picture 81

TWi and Takeda settle dispute over anti-reflux generic

Generics/News | Posted 15/05/2015

Taiwan-based TWi Pharmaceuticals (TWi) announced on 27 April 2015 that it had entered into a settlement agreement with Takeda Pharmaceutical Company, Takeda Pharmaceuticals USA and Takeda Pharmaceuticals America (Takeda) to settle and dismiss all outstanding patent litigation related to TWi’s generic dexlansoprazole.

picture52

FDA approves first generics of antipsychotic drug

Generics/News | Posted 04/05/2015

The US Food and Drug Administration (FDA) announced on 28 April 2015 the approval of the first generics of Otsuka Pharmaceutical’s schizophrenia drug Abilify (aripiprazole).

109 MD002387

IDT Australia gets FDA nod for 23 generics

Generics/News | Posted 17/04/2015

IDT Australia announced on 13 April 2015 that the US Food and Drug Administration (FDA) had accepted the transfer of ownership of 23 generics to the Australia-based company.

Patent 2 V13E31

Shire grabs Par’s attention with patent lawsuit

Generics/News | Posted 03/04/2015

Shire has served its rival Par Pharmaceutical (Par) with a patent infringement lawsuit in New Jersey Federal Court over Par's application to market a generic version of Shire's attention deficit hyperactivity disorder medication Adderall XR.